HIGHLIGHTS
- who: Florian Lordick from the (UNIVERSITY) have published the research work: Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer, in the Journal: (JOURNAL)
- what: The primary study objectives were to explore the pharmacodynamics, including activation and kinetic profiles, of various immune cell populations (i.e., u03b39u03b42 T_cells, NK cells, regulatory T u00ad[Treg] cells, B cells, monocytes) induced by ZA, with or without IL-2, in relation to zolbetuximabinduced activity, and to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.